MOTO - T Cell kurapwa, CAR T Therapy, MOTO T-Cell, chimeric agent
Dive Yakadzika muCAR T Cell Therapy: Inoshanda Sei?
Ziva sainzi kuseri kweCAR T Cell kurapwa muIndia! Ongorora kuti iyi shanduko yekurapa inoshandura sei maseru edziviriro yako kuita cancer fighters. Verenga blog yedu izvozvi kuti udzidze zvakawanda nezve ichi chishamiso kurapa uye sei ..
MOTO - T Cell kurapwa, MOTO T-Cell, Chimeric Mumiriri Anogamuchira, Korea, Seoul, Chammhembe Koria
Makambani muKorea anotora nhanho padyo mukugadzira CAR T-Cell kurapwa
Chivabvu 2023: Chimeric antigen receptor (CAR) T-cell therapy ndeyekuvandudza mundima yemunhu mumwe nemumwe kurapa cancer. Murwere ega T-masero anogadziridzwa genetic panguva yekugadzira maitiro kuratidza ..
hwokushandura zvinhu zvipenyu, MOTO - T Cell kurapwa, MOTO T-Cell, CAR kurapwa, China, fund raise, Oricell Therapeutics
Oricell inokwidza imwe $45M USD kuwedzera CAR T-Cell therapy kuUnited States
Kurume 23, 2023: Makiriniki uye ekutanga-danho rekurapa cancer maseru ari kugadzirwa neShanghai biotech Oricell awana imwe madhora makumi mana neshanu emari, kambani yakazivisa neChipiri. Kutevera kuratidzwa kuAS..
Ositireriya, MOTO - T Cell kurapwa, CAR T Therapy, Cartherics
Peter MacCallum Cancer Center neCartherics vachabatana pagomarara reovarian CAR-T cell therapy.
Kurume 2023: Peter MacCallum Cancer Center (Peter Mac) muAustralia neCartherics Pty Ltd vakapinda muchibvumirano chekudyidzana chirongwa chekuvandudza (CDPA) kugadzira CTH-002 yekurapa gomarara reovarian. The cli..
MOTO - T Cell kurapwa, MOTO T-Cell, Emily Littlejohn, Immunology, lupus renaissance
New CAR T-Cell therapy mushonga mu lupus renaissance
Kukadzi 2024: Mishonga mitsva yakati wandei uye marapirwo anovimbisa, akadai sechimeric antigen receptor T-cell therapy, akaunza "renaissance" ye lupus, sekureva kwemutauri pasymposium Basic uye Clinical Immunology yeBazi ..
anti-BCMA, MOTO - T Cell kurapwa, CT103A, FDA, IASO Biotherapeutics, Innovent Biologics, nherera zita remushonga
CT103A, CAR T-cell Therapy, yakasarudzwa semushonga wenherera neFDA.
Feb 2023: The FDA has granted orphan drug status to CT103A, an experimental CAR T-cell therapy being developed by IASO Biotherapeutics and Innovent Biologics to treat relapsed or refractory multiple myeloma. Orphan drug design..
MOTO - T Cell kurapwa, China, IASO Biotherapeutics, akawanda myeloma
CAR T-sero kurapwa kubva kuIASO Biotherapeutics inogamuchira nyowani FDA mvumo
Kukadzi 2023: IASO Biotherapeutics 'yekuferefeta CAR T-cell therapy yekudzokororwa kana refractory multiple myeloma (RRMM), CT103A, yakagamuchira kukurumidza uye regenerative mushonga wepamusoro kurapa dhizaini kubva kuUS Chikafu uye.
MOTO - T Cell kurapwa, Seoul, Chammhembe Koria
AMC inovhura CAR T-Cell therapy nzvimbo muSeoul
Ndira 2023: Asan Medical Center (AMC) yakavhura nzvimbo yekutanga yeCAR-T yekurapisa maseru munyika mushure mekunge hurumende yabvumidza mabhenefiti einishuwarenzi yehutano yeKymriah's CAR-T cell therapy.
Blood Test, MOTO - T Cell kurapwa, JAMA Oncology, neurofilament chiedza cheni, Neurotoxic Matambudziko, Washington University
CAR T-Cell kurapa matambudziko anogona kufanotaurwa nekuongororwa ropa kuri nyore
Sept 2022: Kurapwa kwemamota akasiyana kwakashandurwa ne cell-based immunotherapy, inowanzozivikanwa seCAR-T cell therapy. Kuti utarise uye urwise mafomu chaiwo eukemia uye lymphoma, kurapwa kunoshandisa genetic.
MOTO - T Cell kurapwa, Iyo kambani CARsgen Therapeutics Co, Daiichi Sankyo Company, DLBCL, Emergen Research, Zvishoma, Novartis AG
CAR T-Cell therapy musika inokura pamwero wepamusoro mumakore masere anotevera
Chikunguru 2022: Zvinoenderana netsvagiridzo yazvino yakaitwa neEmergen Research, musika wepasi rose weCAR T-cells therapy wakasvika pachiyero cheUS $ 1.29 bhiriyoni muna 2021 uye inotarisirwa kunyoresa mari CAGR ye24.9 muzana.